Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Takafumi Yanagisawa; Manuela Schmidinger; Tatsushi Kawada; Kensuke Bekku; Takahiro Kimura; Shahrokh F. Shariat

doi:10.1016/j.euf.2023.01.022

Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Takafumi Yanagisawa, Manuela Schmidinger, Tatsushi Kawada, Kensuke Bekku, Takahiro Kimura, Shahrokh F. Shariat

University Hospital

Research output: Contribution to journal › Review article › peer-review

7 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. Patient summary: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.

Original language	English
Pages (from-to)	275-277
Number of pages	3
Journal	European Urology Focus
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/j.euf.2023.01.022
Publication status	Published - Mar 2023

Keywords

Cytoreductive nephrectomy
Immune checkpoint inhibitors
Metastatic renal cell carcinoma

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euf.2023.01.022

Cite this

@article{7f1cd8be58934ebfb5a6b5804700eddd,

title = "Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma",

abstract = "Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. Patient summary: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.",

keywords = "Cytoreductive nephrectomy, Immune checkpoint inhibitors, Metastatic renal cell carcinoma",

author = "Takafumi Yanagisawa and Manuela Schmidinger and Tatsushi Kawada and Kensuke Bekku and Takahiro Kimura and Shariat, {Shahrokh F.}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = mar,

doi = "10.1016/j.euf.2023.01.022",

language = "English",

volume = "9",

pages = "275--277",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

AU - Yanagisawa, Takafumi

AU - Schmidinger, Manuela

AU - Kawada, Tatsushi

AU - Bekku, Kensuke

AU - Kimura, Takahiro

AU - Shariat, Shahrokh F.

PY - 2023/3

Y1 - 2023/3

N2 - Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. Patient summary: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.

AB - Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. Patient summary: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.

KW - Cytoreductive nephrectomy

KW - Immune checkpoint inhibitors

KW - Metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85150468318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150468318&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2023.01.022

DO - 10.1016/j.euf.2023.01.022

M3 - Review article

C2 - 36775716

AN - SCOPUS:85150468318

SN - 2405-4569

VL - 9

SP - 275

EP - 277

JO - European Urology Focus

JF - European Urology Focus

IS - 2

ER -

Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this